Darunavir
Darunavir is an orally-bioavailable non-peptidic inhibitor of human immunodeficiency virus type 1 (HIV-1) protease that selectively inhibits HIV-1 protease enzyme induced cleavage of gag and gag-pol poly-proteins preventing the maturation of virions and also inhibits the dimerization of HIV-1 protease suppressing proteolytic activity and subsequent replication of HIV-1. Study results have shown that darunavir exhibits potent inhibition against HIV-1 with a value of 50% inhibition concentration IC50 of 0.003 μmol/L in HIV-1 infected MT-2 cells. Darunavir binds to HIV-1 protease with considerably high affinity and fits closely with the substrate envelop leading to its potent ability to inhibit multidrug-resistant HIV strains.
Reference
McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007.
- 1. Velichkovska M, Surnar B, et al. "Targeted Mitochondrial COQ(10) Delivery Attenuates Antiretroviral-Drug-Induced Senescence of Neural Progenitor Cells." Mol Pharm. 2019 Feb 4;16(2):724-736. PMID:30592424
- 2. Lan, Jie, et al. "Provirus Activation Plus CD59 Blockage Triggers Antibody-Dependent Complement-Mediated Lysis of Latently HIV-1–Infected Cells." The Journal of Immunology (2014): 1303030. PMID:25149467
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 547.66 |
| Cas No. | 206361-99-1 |
| Formula | C27H37N3O7S |
| Solubility | ≥22.65 mg/mL in DMSO; insoluble in H2O; ≥4.94 mg/mL in EtOH with ultrasonic |
| Chemical Name | (E)-(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl hydrogen ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbonimidate |
| SDF | Download SDF |
| Canonical SMILES | CC(CN(S(C1=CC=C(N)C=C1)(=O)=O)C[C@](O)([H])[C@](/N=C(O[C@@]2([H])CO[C@]3([H])[C@@]2([H])CCO3)\O)([H])CC4=CC=CC=C4)C |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
MT-2 cells and phytohemagglutinin-activated peripheral blood mononuclear cells (PHA-PBMCs) |
|
Reaction Conditions |
3 nM darunavir (IC50 in MT-2 cells) for 7 d incubation |
|
Applications |
Darunavir was active against HIV-1LAI in MT-2 cells (IC50 = 3 nM) with a 50% cytotoxic concentration (CC50) of 74.4 μM. Darunavir was also active against wild-type and multidrug-resistant clinical isolates of HIV-1 in PHA-PBMCs, with IC50 values being 3 and 3 ~ 29 nM, respectively. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy, 2003, 47(10): 3123-3129. |
|
| Description | Darunavir is an inhibitor of HIV protease. | |||||
| Targets | HIV Protease | |||||
| IC50 | ||||||
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
